Annual report
2370.TEDINET S100XB0H
Period2024-10-01 → 2025-09-30
Filed2025-12-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥810m | 2024-10-01 → 2025-09-30 | Standalone | Net sales |
| Revenue | ¥769m | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥662m | 2022-10-01 → 2023-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥634m | 2021-10-01 → 2022-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥683m | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Operating income |
| Operating income | −¥1.4bn | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Ordinary income | −¥1.3bn | 2024-10-01 → 2025-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.4bn | 2022-10-01 → 2023-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2021-10-01 → 2022-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥871m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Net income | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | −¥1.4bn | 2022-10-01 → 2023-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.3bn | 2021-10-01 → 2022-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | −¥843m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.3bn | at 2025-09-30 | Standalone | Assets |
| Total assets | ¥5.7bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥5.6bn | at 2023-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.1bn | at 2022-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥476m | at 2025-09-30 | Standalone | Liabilities |
| Total liabilities | ¥509m | at 2024-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥3.8bn | at 2025-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.2bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2023-09-30v | Standalone | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-09-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.9bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2025-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2024-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2025-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2024-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2023-09-30v | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2022-09-30v | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.1bn | at 2021-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.3bn | 2022-10-01 → 2023-09-30v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.2bn | 2021-10-01 → 2022-09-30v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥975m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥565m | 2024-10-01 → 2025-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥65m | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥3m | 2022-10-01 → 2023-09-30v | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥20m | 2021-10-01 → 2022-09-30v | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥344m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3m | 2024-10-01 → 2025-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.2bn | 2022-10-01 → 2023-09-30v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.6bn | 2021-10-01 → 2022-09-30v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-5.15 | 2024-10-01 → 2025-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.04 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.65 | 2022-10-01 → 2023-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.33 | 2021-10-01 → 2022-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.88 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥14.27 | at 2025-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥19.62 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.64 | at 2023-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥26.03 | at 2022-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.31 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 88.8% | at 2025-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.1% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.2% | at 2023-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2022-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.8% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -30.4% | 2024-10-01 → 2025-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -25.0% | 2023-10-01 → 2024-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.3% | 2022-10-01 → 2023-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -24.1% | 2021-10-01 → 2022-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -17.5% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 264,729,198 | at 2025-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 264,515,306 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 232,160,757 | at 2023-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 211,730,423 | at 2022-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 178,750,423 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 107 | at 2025-09-30 | Standalone | Number of employees |
| Employees | 112 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 98 | at 2023-09-30v | Standalone | Number of employees |
| Employees | 96 | at 2022-09-30v | Standalone | Number of employees |
| Employees | 83 | at 2021-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-10-01 → 2025-09-30 | ¥4m |
| Reconciling Itemsreconciling | depreciation | 2024-10-01 → 2025-09-30 | ¥15m |
| Reconciling Itemsreconciling | segment assets | at 2025-09-30 | ¥3.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-09-30 | −¥563m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2024-10-01 → 2025-09-30 | ¥3m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2024-10-01 → 2025-09-30 | ¥22m |
| Cellular And Tissue Based Product Businessreportable segment | employees | at 2025-09-30 | 16 pure |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥219,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥219,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2025-09-30 | ¥139m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2024-10-01 → 2025-09-30 | −¥408m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2024-10-01 → 2025-09-30 | ¥20m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2024-10-01 → 2025-09-30 | ¥64m |
| Contracted Cell Manufacturing Businessreportable segment | employees | at 2025-09-30 | 78 pure |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥810m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥810m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2025-09-30 | ¥687m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2024-10-01 → 2025-09-30 | −¥475m |
| —segment total | capex | 2024-10-01 → 2025-09-30 | ¥24m |
| —segment total | depreciation | 2024-10-01 → 2025-09-30 | ¥86m |
| —segment total | revenue | 2024-10-01 → 2025-09-30 | ¥810m |
| —segment total | revenue external | 2024-10-01 → 2025-09-30 | ¥810m |
| —segment total | segment assets | at 2025-09-30 | ¥826m |
| —segment total | segment profit | 2024-10-01 → 2025-09-30 | −¥883m |
| Reconciling Itemsreconciling | capex | 2023-10-01 → 2024-09-30 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2023-10-01 → 2024-09-30 | ¥18m |
| Reconciling Itemsreconciling | segment assets | at 2024-09-30 | ¥4.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-09-30 | −¥577m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥21m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥36m |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥245,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥245,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2024-09-30 | ¥116m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | −¥435m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥23m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥61m |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥768m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥768m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2024-09-30 | ¥667m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | −¥374m |
| —segment total | capex | 2023-10-01 → 2024-09-30 | ¥44m |
| —segment total | depreciation | 2023-10-01 → 2024-09-30 | ¥97m |
| —segment total | revenue | 2023-10-01 → 2024-09-30 | ¥769m |
| —segment total | revenue external | 2023-10-01 → 2024-09-30 | ¥769m |
| —segment total | segment assets | at 2024-09-30 | ¥783m |
| —segment total | segment profit | 2023-10-01 → 2024-09-30 | −¥808m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 961
| Item | Context | Value | Unit |
|---|---|---|---|
| Assets | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 686582000 | JPY |
| Assets | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 139494000 | JPY |
| Assets | CurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember | 826076000 | JPY |
| Assets | CurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember | 3427993000 | JPY |
| Assets | CurrentYearInstant_NonConsolidatedMember | 4254070000 | JPY |
| Depreciation segment information | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 64186000 | JPY |
| Depreciation segment information | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 21926000 | JPY |
| Depreciation segment information | CurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember | 86112000 | JPY |
| Depreciation segment information | CurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember | 15451000 | JPY |
| Depreciation segment information | CurrentYearDuration_NonConsolidatedMember | 101563000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 20463000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 3342000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_NonConsolidatedMember_ReportableSegmentsMember | 23806000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember | 4287000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_NonConsolidatedMember | 28093000 | JPY |
| Impairment loss el | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 25366000 | JPY |
| Impairment loss el | CurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | － | JPY |
| Impairment loss el | CurrentYearDuration_NonConsolidatedMember_UnallocatedAmountsAndEliminationMember | － | JPY |
| Impairment loss el | CurrentYearDuration_NonConsolidatedMember | 25366000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-12-17 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第30期（自 2024年10月１日 至 2025年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社メディネット | |
| Company name in english cover page | FilingDateInstant | MEDINET Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 久布白 兼直 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都品川区勝島一丁目５番21号（同所は登記上の本店所在地であり、実際の業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都大田区平和島六丁目１番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)（０３）６６３１－１２０１（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理部長 落合 雅三 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05351 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 23700 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社メディネット | |
| Filer name in english | FilingDateInstant | MEDINET Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2024-10-01 | |
| Current period end date | FilingDateInstant | 2025-09-30 | |
| Type of current period | FilingDateInstant | FY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |